Galena
Biopharma recently captured the attention of Motley Fool writer Ted Mayer who
begins his opine by noting that investors can make wise investment decision by
watching what institutional investors are doing. A watchful eye in this case,
he says, starts by burrowing through SEC filings.
“Over
the past few months, Galena Biopharma has gotten a lot of attention as it is
developing several promising cancer treatments. Since the end of September,
shares of the company have soared by more than 120%,” writes Mayer. “This has
increased the value of the company by more than $230 million. After looking at
the recent investment fund filings, it looks like one of the big reasons for
the move has been increased institutional investment. A few of the funds that
have recently added shares are Barclays Global, Blackrock, Highland Capital
Management, Bridgeway Capital Management, Dafna Capital Management, and UBS
O’Connor.”
To
read the full article visit
http://www.fool.com/investing/small-cap/2013/12/10/investment-funds-are-taking-a-big-stake-in-galena.aspx
The
article recaps each fund’s current stake in Galena, citing the company’s
advancements and outlook.
“This
is an impressive list of investors that have upped their holdings.
Additionally, the overall trend by institutions is impressive. During the most
recent quarter, 18 new positions were initiated compared to just five closings.
… This is likely due to both the company’s recent progress and the potential
that it has demonstrated,” he writes.
Mayer
also highlights Galena’s breast cancer drug candidate, NeuVax, which is
currently in a phase 3 PRESENT trial. He notes that current estimates are that
upon FDA approval NeuVax could treat between 80,000 -120,000 new cases of
breast cancer each year.
For
more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
